The relationship between BLyS protein levels and response to belimumab was demonstrated in a previous post hoc analysis of the BLISS studies [17], and these data are in keeping with a prospective study that demonstrated greater disease activity with higher levels of BLyS protein in patients with SLE [6]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.